| Literature DB >> 32767466 |
Efsun Tanacan1, Gulhan Aksoy Sarac1, Mehmet Ali Can Emeksiz1, Didem Dincer Rota1, Fatma Gulru Erdogan1.
Abstract
The aim of this study was to evaluate the changing trends in dermatology clinical practice at a tertiary center during the coronavirus disease 2019 (COVID-19) pandemic. This retrospective cohort study was conducted on patients who were admitted to Ufuk University Hospital with dermatologic complaints/diseases before and during the pandemic. The patients were divided into two groups: (a) the pre-pandemic period (March-May 2019) and (b) the Pandemic period (March-May 2020). Demographic features, clinical characteristics, dermatologic diseases/complaints, dermatologic procedures/interventions, hospitalization rate, and use of biologic agents were compared between the two groups. Total number of hospital admissions have decreased from 1165 to 717. Admission rates for acne, dermatophytosis, and benign neoplasm of the skin significantly lower during the pandemic period (P values were .02, .04, and .006, respectively). Contact dermatitis, acne accompanying dermatitis, cicatricial hair loss, lichen planus, and zona zoster infection rates were significantly higher (P values were .007, <.001, .009, .04, and .03, respectively). Rates of biopsy and electrocautery procedures were decreased significantly (P values were <.001 and .002, respectively). The hospitalization rate was similar between the groups (P = .51). However, the use of biologic agents significantly decreased during the pandemic period (P = .01). Updated clinical protocols should be established for the new normal period in accordance with these findings.Entities:
Keywords: COVID-19; changing clinical practice; dermatology; pandemic
Mesh:
Substances:
Year: 2020 PMID: 32767466 PMCID: PMC7435568 DOI: 10.1111/dth.14136
Source DB: PubMed Journal: Dermatol Ther ISSN: 1396-0296 Impact factor: 3.858
Demographic features and clinical characteristics of the patients
| Variables | Pre‐pandemic (March–May 2019) (n = 1165) | Pandemic (March–May 2020) (n = 717) |
|
|---|---|---|---|
| Age group (n, %) | .71 | ||
| <20 years | 209 (17.9%) | 123 (17.2%) | |
| 20–65 years | 815 (70%) | 514 (71.7%) | |
| >65 years | 141 (12.1%) | 80 (11.2%) | |
| Gender (n, %) | .62 | ||
| Female | 767 (65.8%) | 464 (64.8%) | |
| Male | 398 (34.2%) | 252 (35.2%) | |
| Number of hospital admissions (n, %) |
| ||
| 1 | 1058 (90.8%) | 657 (91.6%) | |
| 2 | 75 (6.4%) | 58 (8.1%) | |
| 3 | 32 (2.7%) | 2 (0.3%) | |
| Number of dermatologic diseases/complaints (n, %) |
| ||
| 1 | 979 (84%) | 523 (72.9%) | |
| 2 | 168 (14.4%) | 178 (24.8%) | |
| 3 | 18 (1.6%) | 14 (2.2%) | |
Comparison of dermatologic diseases/complaints between the pandemic and pre‐pandemic period
| Variables | Pre‐pandemic (March–May 2019) (n = 1165) | Pandemic (March–May 2020) (n = 717) |
|
|---|---|---|---|
| Acne | 283 (23.4%) | 141 (19.7%) |
|
| Dermatophytosis | 114 (9.8%) | 51 (7.1%) |
|
| Benign neoplasm of the skin | 87 (7.5%) | 31 (4.3%) |
|
| Contact dermatitis | 67 (5.8%) | 71 (9.9%) |
|
| Wart | 59 (5.1%) | 42 (5.9%) | .45 |
| Psoriasis | 52 (4.5%) | 21 (2.9%) | .09 |
| Rosacea | 51 (4.4%) | 19 (2.6%) | .06 |
| Non‐scarring alopecia/hair loss | 57 (4.9%) | 32 (4.5%) | .67 |
| Nail disorders with/without onychomycosis | 54 (4.6%) | 33 (4.6%) | .97 |
| Pruritus | 37 (3.1%) | 34 (4.7%) | .08 |
| Urticaria | 30 (2.6%) | 18 (2.5%) | .93 |
| Xeroderma | 29 (2.5%) | 15 (2.1%) | .57 |
| Seborrheic dermatitis | 27 (2.3%) | 20 (2.8%) | .52 |
| Cutaneous infection and infestation | 21 (1.8%) | 21 (2.9%) | .10 |
| Melasma/postinflammatory hyperpigmentation | 21 (1.8) | 8 (1.1%) | .24 |
| Atopic dermatitis | 17 (1.5%) | 12 (1.2%) | .71 |
| Malign neoplasm of the skin | 15 (1.3%) | 5 (0.7%) | .22 |
| Aphthous stomatitis | 15 (1.3%) | 8 (1.1%) | .74 |
| Acne and dermatitis | 13 (1.1%) | 44 (6.1%) |
|
| Nevus/ephelid/lentigo | 13 (1.1%) | 4 (0.6%) | .21 |
| Bullous dermatitis | 10 (0.9%) | 6 (0.8%) | .96 |
| Vitiligo | 10 (0.9%) | 9 (1.3%) | .52 |
| Actinic keratosis | 6 (0.5%) | 5 (0.6%) | .61 |
| Behçet's disease | 9 (0.8%) | 3 (0.4%) | .34 |
| Drug eruption, leukocytoclastic vasculitis and reactive dermatosis | 11 (0.9%) | 6 (0.8%) | .81 |
| Cicatricial hair loss | 0 (0%) | 6 (0.8%) |
|
| Pityriasis rosea | 5 (0.4%) | 3 (0.4%) | .97 |
| Lichen planus | 5 (0.4%) | 9 (1.3%) |
|
| Atrophic disorders of the skin, Connective tissue disease | 10 (0.9%) | 5 (0.7%) | .70 |
| Hidradenitis suppurativa | 4 (0.3%) | 2 (0.3%) | .80 |
| Herpes simplex infection | 9 (0.8%) | 9 (1.3%) | .29 |
| Zona zoster infection | 12 (1%) | 16 (2.2%) |
|
| Others | 12 (1%) | 9 (1.3%) | .65 |
Comparison of dermatologic procedures/interventions between the pandemic and pre‐pandemic period
| Variables | Pre‐pandemic (March–May 2019) (n = 1165) | Pandemic (March–May 2020) (n = 717) |
|
|---|---|---|---|
| Cryotherapy | 86 (7.4%) | 37 (5.2%) | .058 |
| Biopsy | 66 (5.7%) | 13 (1.8%) |
|
| Electrocautery | 16 (1.4%) | 0 (0%) |
|
| Intralesional injection | 25 (2.1%) | 7 (0.9%) | .18 |
| Patch/prick test | 6 (0,5%) | 0 (0%) | .054 |
Comparison of hospitalization rate and use of biologic agents between the pandemic and pre‐pandemic period
| Variables | Pre‐pandemic (March–May 2019) (n = 1165) | Pandemic (March‐May 2020) (n = 717) |
|
|---|---|---|---|
| Hospitalization rate (%) | 20 (1.7%) | 9 (1.1%) | .51 |
| Use of biologic agents (%) | 25 (2.1%) | 5 (0.6%) |
|